Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Moodys
Colorcon
Express Scripts

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for LY3023414


Email this page to a colleague

« Back to Dashboard

What is the drug development status for LY3023414?

LY3023414 is an investigational drug.

There have been 17 clinical trials for LY3023414. The most recent clinical trial was a Phase 2 trial, which was initiated on July 31st 2017.

The most common disease conditions in clinical trials are Neoplasms, Lymphoma, Non-Hodgkin, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Eli Lilly and Company, National Cancer Institute (NCI), and SCRI Development Innovations, LLC.

There are four US patents protecting this investigational drug and ninety-two international patents.

Recent Clinical Trials for LY3023414
TitleSponsorPhase
Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By PrexasertibEli Lilly and CompanyPhase 2
Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By PrexasertibBaylor Research InstitutePhase 2
Abemaciclib With Letrozole in Recurrent or Persistent Endometrial CancerEli Lilly and CompanyPhase 2

See all LY3023414 clinical trials

Clinical Trial Summary for LY3023414

Top disease conditions for LY3023414
Top clinical trial sponsors for LY3023414

See all LY3023414 clinical trials

US Patents for LY3023414

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY3023414 ⤷  Sign up for a Free Trial Selective estrogen receptor degraders Eli Lilly and Company (Indianapolis, IN) ⤷  Sign up for a Free Trial
LY3023414 ⤷  Sign up for a Free Trial Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile Loxo Oncology Inc. (Stamford, CT) ⤷  Sign up for a Free Trial
LY3023414 ⤷  Sign up for a Free Trial PI3 kinase/mTOR dual inhibitor Eli Lilly and Company (Indianapolis, IN) ⤷  Sign up for a Free Trial
LY3023414 ⤷  Sign up for a Free Trial PI3 kinase/mTOR dual inhibitor Eli Lilly and Company (Indianapolis, IN) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY3023414

Drugname Country Document Number Estimated Expiration Related US Patent
LY3023414 Argentina AR115694 2038-07-12 ⤷  Sign up for a Free Trial
LY3023414 Australia AU2019299947 2038-07-12 ⤷  Sign up for a Free Trial
LY3023414 Australia AU2019299952 2038-07-12 ⤷  Sign up for a Free Trial
LY3023414 Brazil BR112020025381 2038-07-12 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Moodys
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.